CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 31 enrolled
Drug / intervention
Elimusertibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05071209
NCT05071209Phase 2Active
CompareCT.gov

A Phase 1/ 2 Study of BAY 1895344 (Elimusertib, NSC#810486) in Pediatric Patients With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)·interventional·Posted Oct 8, 2021·Updated Jan 23, 2026

In Brief

A Phase 2 clinical trial evaluating Elimusertib for Recurrent Alveolar Rhabdomyosarcoma and 7 related conditions. Active but no longer recruiting, targeting 31 participants across 29 sites in 2 countries.

Detailed Summary

This phase I/II trial tests the safety, best dose, and whether elimusertib works in treating patients with solid tumors that have come back (relapsed) or does not respond to treatment (refractory). Elimusertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Refractory Alveolar Rhabdomyosarcoma, Refractory Ewing Sarcoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
CountriesCanada, United States
Collaborators--

Timeline

Phase 2ActiveOverdue
20222023202420252026
First PostedOct 8, 2021
Enrollment StartDec 22, 2021
Primary CompletionSep 30, 2024
Study CompletionMar 31, 2026
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 4.7 years ago

Interventions

Elimusertibdrug

Given PO